Evidence map›Paper›PMID 41889506›Full record

ArticleFrontiers in medicine2026

Validation of

C M Morales-Álvarez, A C Jiménez-Domínguez, R M Rios-Pelegrina, E Arance, F Marín-Benesiu, F Vázquez-Alonso, L J Martínez-González, M J Álvarez-Cubero

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

C M Morales-Álvarez *Department of Biochemistry and Molecular Biology III, Faculty of Medicine, PTS Granada, University of Granada, Granada, Spain.
A C Jiménez-Domínguez *Department of Biochemistry and Molecular Biology III, Faculty of Medicine, PTS Granada, University of Granada, Granada, Spain.
R M Rios-PelegrinaDepartment of Pathology, Hospital Clínico San Cecilio, Granada, Spain.
E AranceDepartment of Biochemistry and Molecular Biology III, Faculty of Medicine, PTS Granada, University of Granada, Granada, Spain.
F Marín-BenesiuDepartment of Biochemistry and Molecular Biology III, Faculty of Medicine, PTS Granada, University of Granada, Granada, Spain.
F Vázquez-AlonsoDepartment of Urology, University Hospital Virgen de las Nieves, Granada, Spain.
L J Martínez-GonzálezDepartment of Biochemistry and Molecular Biology III, Faculty of Medicine, PTS Granada, University of Granada, Granada, Spain.
M J Álvarez-CuberoDepartment of Biochemistry and Molecular Biology III, Faculty of Medicine, PTS Granada, University of Granada, Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Renal cell carcinoma (RCC) is a heterogeneous malignancy influenced by genetic and environmental factors. Previous genome-wide association studies (GWAS) have identified risk single nucleotide polymorphisms (SNPs) associated with RCC susceptibility, particularly within genes such as Methods: This study analyzed five GWAS-identified SNPs-rs1049380 and rs10771279 ( Results: The C/C genotype of Conclusion: This study provides independent evidence supporting the biological relevance of GWAS-identified loci in RCC. While several variants showed nominal associations with disease risk,

Indexed as

biomarkersDPF3EPAS1ITPR2renal cell carcinomaSNPs

Identifiers

PMID41889506
PMCPMC13012921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.